PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Front Biosci. Author manuscript; available in PMC 2010 May 11.
Published in final edited form as:
PMCID: PMC2867599
NIHMSID: NIHMS193503

Mechanisms of chronic rejection in cardiothoracic transplantation

Abstract

Despite significant improvements in early post-transplantation survival rates, long-term patient and graft survival have remained poor, due in large part to the vexing problem of chronic allograft rejection. Attempts to combat this problem with intensification of immunosuppression have led to concomitant increases in the rates of fatal malignancies and infections. In cardiac transplantation, chronic rejection is manifested primarily by a disease entity known as cardiac allograft vasculopathy, an occlusive narrowing of the coronary vessels. In lung transplantation, chronic rejection is typified by obliterative bronchiolitis, an airflow limiting narrowing of the bronchioles. From an immunologic standpoint, chronic rejection is believed to be the end result of repeated immune and non-immune insults to the graft. This review examines the pathophysiology of heart and lung chronic, with emphasis on both immune and non-immune causes.

Keywords: Transplantation, Chronic Rejection, Heart, Lung, Review

2. Introduction

With the advent of modern immunosuppression, early post-transplantation graft and patient survival rates have improved dramatically over the last quarter of a century. However, long-term graft survival remains poor, with overall graft half-lives currently being 9.9 years for hearts, and 5 years for lungs (1,2). The majority of post-transplant deaths can be attributed to either chronic rejection (CR) or malignancy. The clinical impact of CR is most evident in the field of cardiothoracic transplantation, where re-transplantation for failed grafts is usually not possible because of the relatively small donor pool. Data from the International Society for Heart and Lung Transplantation (ISHLT) demonstrate a linear decrement in both patient and allograft survival for recipients of cardiothoracic organs after the first post-transplant year, which continues for at least 15 years. By the fifth post-transplant year, cardiac allograft vasculopathy (CAV) and subsequent graft failure account for 30% of deaths in heart transplant recipients (1). Tor lungs, the bronchiolitis obliterans syndrome (BOS) is the predominant cause of death after the first post-transplant year (2). Mortality not withstanding, the morbidity of those that survive with BOS is considerable. Given the clear toll that CR takes on heart and lung graft recipients, research is currently underway to understand the pathogenesis of CR in the hope of developing both preventive and therapeutic strategies. This chapter examines the pathophysiology of heart and lung CR, with emphasis on both immune and non-immune causes.

3. Histology and Pathophysiology of Chronic Rejection

The diagnosis of CR has historically relied on invasive procedures to obtain graft biopsies for histological evaluation. Regardless of the type of vascularized allograft, organs undergoing CR manifest similar pathological findings: obliterative vasculopathy, infiltration of leukocytes, luminal occlusion, and a marked fibrotic response. These histologic findings are the final result of a complex, multi-stage process of repeated immune- and non-immune-mediated cellular injury and inflammation. Repetitive insults exhaust the recipient's natural repair mechanisms and result in fibrotic replacement and organ failure. The fibrosis appears to preferentially narrow and obliterate the endothelial- and epithelial-lined tubular structures in the graft.

In heart allografts, the principal histological and clinical manifestations of CR consist of concentric vasculopathy with smooth muscle cell proliferation, together known as cardiac CAV. These intimal changes can be detected by intravascular ultrasound, which is becoming the gold standard for early diagnosis (3). As the disease progresses, myointimal proliferation eventually occludes coronary vessels, resulting in infarction and ischemic cardiomyopathy. Although it is believed that antigen-independent (4) and autoimmune (5,6) factors can contribute to CAV, CAV is predominately incited by an antigen-dependent stimulus (4,7).

In the lung, CR leads to histologic lesions of obliterative bronchiolitis (OB), which presents clinically as BOS. OB is a concentric fibrosis of the membranous and respiratory bronchioles that results in an obstructive defect to airflow. The histopathologic features of OB include inflammation of the epithelial cells and subepithelial structures, believed to result from aberrant tissue repair (8). In severe chronically rejecting lung allografts, fibrosis can extend into the interstitium and may involve the pulmonary vasculature in a process similar to CAV.

4. Alloimmunity

Most investigators currently believe that that immune-mediated injuries to the graft are the fundamental cause of CR (9). The immune response to an allograft is initiated by T cells, which, when activated, can orchestrate a cytotoxic cellular response, as well as providing help for antibody production by B cells. Understanding antigen targets and mechanisms by which T cells respond to allogeneic material is crucial to the elucidation of the pathogenesis of solid-organ CR.

Alloantigens are able to activate T cells via two pathways. “Direct allorecognition” refers to the process by which intact donor major histocompatibility complex (MHC)-peptide complexes are recognized on donor antigen presenting cells (APCs) by host T cells. This type of recognition is unique to transplantation. Alternatively, the “indirect allorecognition” pathway occurs when donor MHC molecules or minor antigens are processed into peptides and presented to host T cells by host APCs. Many scientists believe that early acute rejection is predominantly mediated by the direct pathway. As time passes, the donor-derived passenger APCs that were transplanted with the graft are depleted and indirect allorecognition predominates. Swine studies have demonstrated that pre-transplant immunization with donor-derived MHC peptides accelerates rejection in both heart (10) and lung allografts (13). Furthermore, the immunodominance of various donor antigens changes over time during the rejection process, as has been shown in human recipients (11-13). These findings emphasize that indirect allorecognition likely plays a critical role in the development of CR.

4.1. HLA matching

The degree of immune disparity between the host and donor is the dominant predictor of the incidence and vigor of CR. Early clinical observations have now been confirmed in experimental studies that show that isografts remain free of CR, while recipients intentionally sensitized to donor antigen develop accelerated chronic and acute rejection (14). In renal transplantation, organ allocation is partially driven by human leukocyte antigen (HLA) matching because of the significantly improved graft survival seen with higher degrees of HLA matching (15,16). In contrast, allocation based on HLA matching for thoracic organs has been problematic due to shorter permissible ischemic times and a relatively smaller donor pool. Nonetheless, retrospective data has emerged that demonstrates a significant improvement in cardiac graft survival when recipients are HLA matched. Hosenpud and colleagues performed a retrospective review of the United Network for Organ Sharing (UNOS)/ISHLT registry and demonstrated that HLA matching would be beneficial in cardiac transplantation (17). Opelz and colleagues showed that the extent of HLA compatibility influences graft survival, independent of other variables (18). Kaczmarek and colleagues found that HLA-DR matching improves survival after heart transplantation by as much as 25% within 3 years (19). Finally, data from the ISHLT registry indicate that, in addition to HLA-DR, mismatches at the HLA-B locus predict reduced survival, as measured 10 years following transplantation (1). These findings, coupled with the advent of more precise and rapid tissue typing techniques, may soon refine the way in which cardiac allografts are allocated.

For lung allografts, there is currently insufficient data to draw definitive conclusions on HLA matching. Some studies report no association (20,21). However, three studies initially suggested a significant positive association exists between mismatching at the HLA-A locus and the development of BOS (22-24). More recently, HLA matching was shown to independently impact survival in single-lung transplantation (17). The most recent report from the registry of the ISHLT clearly demonstrates a detrimental effect of mismatches at the HLA-A and HLA-B loci (2). More information regarding HLA typing for lung transplantation should be forthcoming, as the total number of lung transplants performed with known HLA haplotypes increases.

4.2. Acute cellular rejection

Acute rejection (AR) has been clearly demonstrated to be a harbinger of future CR in most solid organ transplants. For lung transplantation, it is widely accepted that AR is a risk factor for both OB and BOS, and this relationship is believed to be causal (25). Several studies have identified severe AR, recurrent episodes of rejection, the cumulative burden of AR, and late AR as risk factors for BOS (20,24,26-29). More recently, a single episode of mild AR was found to be an independent risk factor for the development of BOS (30).

The association between AR and CR in cardiac transplantation was debated for years because early studies had relatively low statistical power and produced equivocal findings (31). However, in recent years, the link between AR and CAV has been further defined for AR episodes both within the first postoperative year (32-34) and later years (35,36). Jimenez and colleagues showed that the biopsy rejection score correlated with the rate of CAV progression as measured by intravascular ultrasound (33). The mechanism is likely one of inflammation and failed repair, but whether it is the frequency and/or the severity of the AR episodes that influences the development of CAV remains to be determined.

4.3. Humoral alloimmunity

The role of B cells and alloantibody formation in the rejection of allografts has been underappreciated. Emerging evidence suggests that alloreactive B cells and anti-HLA antibodies are seminal components of the rejection process (37). Importantly, memory alloreactive B cells can persist for years after the initial immunizing event and therefore have the potential to initiate CR at any time, even years after the initial inciting event. In heart grafts, the development of anti-HLA antibodies is known to correlate with CAV development (38). B cells have been identified in lung tissue during rejection episodes, and anti-HLA antibodies also correlate with the development of OB (39,40). However, the mechanism by which humoral alloimmunity leads to CR is not well understood, and whether the presence of antibody is an initiating event or merely a response to tissue damage remains to be determined. However, the principal target of humoral immunity appears to be the graft endothelium, which can be activated and injured by alloreactive antibodies.

4.4. Progenitor cells and CAV

There is emerging evidence that extracardiac progenitor cells may also contribute to both beneficial and deleterious repair after graft injury. In fact, by studying sex-mismatched heart transplants, investigators now believe that as much as 0.04% of cardiomyocytes in transplanted hearts may actually be of extracardiac recipient origin (41). In addition, animal data on both aortic and cardiac allografts suggest a role for circulating progenitor cells in neointimal proliferation and CAV (42-44). The implication is that these progenitor cells migrate to areas of vascular damage and differentiate into the smooth muscle cells seen in the neointimal proliferation of CAV. However, the data on the contribution of extracardiac progenitor cells to CAV development is conflicting and remains an active area of research today.

4.5. Innate immunity

Recent studies, suggest that the adaptive immune system is not always solely responsible for CAV formation, as mice with T and B cells rendered fully unresponsive to donor antigens through the induction of neonatal tolerance or mixed chimerism still developed CAV (45). We utilized a novel system of semi-allogeneic cardiac transplants between parental donors and Fl hybrid recipients to provide the first evidence that natural killer (NK) cells, members of the innate immune system, also contribute to the generation of CAV in mice. Since NK cells are not targeted by current immunosuppressive therapy, including cyclosporine (46), these findings may explain why CAV, a primarily MHC-driven alloimmune process, still occurs in heavily immunosuppressed recipients. Indeed, the apparent resistance of NK cells to the modulating effects of conventional immunosuppression is compatible with the hypothesis that innate immunity may be an important part of the complex set of events that result in this vexing problem.

4.6. Organ procurement and implantation

A large number of clinical studies have demonstrated a deleterious effect of prolonged ischemic times on transplant outcomes, and thoracic grafts appear to be particularly sensitive to prolonged ischemia. Data from the ISHLT registry historically demonstrates that prolonged ischemic time (>7h) confers an increased risk of BOS development three years after transplantation (47), and ischemic times greater than 7 h for donor hearts increases the risk of both one- and five-year mortality (48). Prolonged ischemia time as a risk factor for decreased graft survival has also been confirmed in more recent registry data (49,50). Ischemic injury not only causes direct acute injury to the graft, but also probably increases the antigenicity of the graft by inducing inflammatory mediators (51), adhesion molecules, and MHC antigens on the graft endothelium (52). As a result, it is likely that ischemia-reperfusion can lead to chronic rejection by actually initiating an immune response. This immune response could be alloimmune or even autoimmune, as can be seen when normally cryptic antigens such as cardiac myosin or type-5 collagen become exposed (see below).

5. Autoimmunity

Itzutani and colleagues showed that chronic rejection was not abrogated by transplanting heart grafts into syngeneic mice (53), suggesting that CR can occur in the absence of alloantigen. Just as a cellular insult to the graft could initiate an alloimmune response, emerging evidence suggests that certain injuries can expose self-antigens that the recipient's immune system does not normally encounter. Since these normally cryptic non-MHC antigens also exist in normal host tissue, this mode of graft rejection can be considered to be autoimmune mediated.

Cardiac myosin is an autologous contractile protein found in cardiac tissue that is recognized by both T and B cells during a cardiac rejection process (54). Fedoseyeva and colleagues showed that anti-cardiac myosin reactivity persists long after transplantation and hypothesized that it may play a role in CAV pathogenesis. They later supported this data with a murine study, which showed that in the absence of alloimmunity, chronic rejection was associated with a T cell response to cardiac myosin (6). Another tissue specific antigen that has been implicated in the formation of CAV is the endothelial antigen vimentin (55).

Analogous to cardiac myosin, researchers have found that immunity during lung allograft rejection involves the development of a response to collagen V (56), which is a component of the perivascular and peribronchial connective tissue. Collagen V reactive lymphocytes are known to express the pro-inflammatory cytokines IL-17 and IL-23 (57), and Wilkes and colleagues have demonstrated that oral tolerance induction to collagen V can prevent BOS development in murine models (58).

6. Infection

Another mechanism of tissue injury and inflammation that plays a role in the development of CR is infection. It has been suggested by several studies that viral respiratory infections, including the common community acquired infections of parainfluenza virus, respiratory syncytial virus, influenza, and adenovirus, are associated with the development of BOS (29,59,60). Cytomegalovirus (CMV) also seems to promote chronic vascular rejection of most solid organ transplants including heart and lung grafts. CMV can invade the endothelium of organs; and therefore, it is not surprising that its presence is associated with perivascular inflammation. Sequence homologies between the immediate early-2 region of CMV, and a conserved domain of HLA-DR (61) and the heavy chain of the MHC class 1 antigen can lead to immunologic cross-reactivity (61). Schulman and colleagues also found a clear role for CMV pneumonitis in the development of BOS, while studying HLA mismatching (62). Thankfully, the use of sensitive and quantitative assays to detect CMV antigenemia and appropriate prophylaxis with antiviral agents now seems to be reducing the impact of CMV infection in BOS development (63).

The most frequently studied infections related to CAV development are C. pneumoniae and CMV. Patients with PCR positivity and antibody formation for C. pneumoniae were found to have more severe CAV (64). Likewise, CMV has been associated with a 28% rate of obstructive CAV five years after heart transplantation; almost triple the rate for non-infected patients (65). More importantly, CMV prophylaxis with ganciclovir decreases the prevalence of CAV (66).

7. Gastroesophageal Reflux Disease and Bronchiolitis Obliterans Syndrome

It has been suggested that GERD, as an inflammatory condition, may contribute to the development of BOS (67,68). A review of lung transplant recipients at Duke University revealed that the presence of GERD is associated with decreased survival and higher rejection rates (68). Interestingly, prophylactic anti-reflux surgery successfully reduced the incidence of allograft dysfunction. The association between GERD and lung allograft dysfunction was confirmed in a rat model by the same group (69). The hypothesis is that a non-alloimmune injury caused by the exposure of bronchial epithelium to caustic gastric fluid precipitates an alloimmune injury. Although the mechanism may only be due to direct toxicity, it may also involve stimulation of the innate and adaptive immune responses. The mechanisms responsible for GERD induced BOS remain elusive.

8. Donor Factors

There is little doubt that the quality of grafted organ can influence late outcomes. This is particularly true when donor organs are relatively undersized or when older donors with co-morbidities are utilized. Some have suggested that a combination of both immune and nonimmune mediated injuries to the graft prior to transplantation leads to insults in the graft that exhaust its repair capacity (70).

8.1. Brain death

Increasing data are accumulating that indicate that brain death induces the expression of inflammatory mediators in peripheral organs, eventually making these organs more susceptible to MHC-driven processes (71). Compared to controls in a rat transplant model, organs harvested from brain-dead donors seem to induce a more intense and accelerated recipient immune response (72). Implicated in this increased alloreactivity were macrophage-associated cytokines and upregulated adhesion molecules (72). More recently, a rat model was used to show that brain death induces an inflammatory response in donor lung grafts and subsequently aggravates chronic rejection (73). A similar increase in inflammatory mediators has been demonstrated in kidneys and livers from brain-dead donor rats. Anyanwu and colleagues also reported a favorable difference in CAV between living and cadaveric donors in an experimental heart transplant model (74). Segel and colleagues have shown that endothelial inflammation and dysfunction occurs as a consequence of brain death even in the absence of hemodynamic instability (75). In the clinical arena, it has been observed that pediatric lung transplant recipients of living donors had a much lower incidence of CR than those from cadaveric donors (76). Studies are now underway evaluating the role of different forms of brain death on the development of CAV in hopes of developing pre-transplant modalities to limit brain-death induced vascular injury to allografts (77).

9. Conclusion

CR is a very complex problem that continues to limit the long-term success of solid organ transplantation, particularly cardiothoracic organs. This chapter highlights new findings that contribute to our current knowledge of the mechanisms of chronic rejection in cardiothoracic organs. Pathologically, CR represents the end result of repeated injury, leading to parenchymal fibrosis and luminal obliteration. The causes of CR resulting from graft tissue injury are multifactorial. Both immunologic and non-immunologic factors contribute to graft injury, which fuels the alloimmune response, predisposing the development of CR. Significant progress has occurred over the past decade to understand the mechanisms of CR development. We now know that in addition to cellular alloimmune responses, autoimmunity may play a role. Recently, the role of humoral alloimmunity has also become apparent. In addition, tissue injury from ischemia/reperfusion, infections, and brain death appears to render the graft more antigenic and susceptible to CR. Further study of all the contributing factors is crucial for understanding the mechanisms by which CR rejection develops in cardiothoracic allografts. All of these factors are potential therapeutic targets.

Acknowledgments

This work was supported in part by National Institute of Health grants from the National Heart, Lung and Blood Institute (RO1HL054211, RO1HL67110, RO1HL071932, PO1HL8646) and the National Institute of Allergy and Infectious Disease (U19A1066705).

Abbreviations

CR
chronic rejection
ISHLT
International Society for Heart and Lung Transplantation
CAV
cardiac allograft vasculopathy
BOS
bronchiolitis obliterans syndrome
OB
obliterative bronchiolitis
APC
antigen presenting cell
MHC
major histocompatibility complex
HLA
human leukocyte antigen
AR
acute rejection
NK
natural killer
CMV
cytomegalovirus

References

1. Taylor DO, Edwards LB, Boucek MN, Trulock EP, Waltz DA, Keck BM, Hertz MI. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult heart transplantation report--2006. J Heart Lung Transplant. 2006;25:869–879. [PubMed]
2. Trulock EP, Edwards LB, Taylor DO, Boucek MN, Keck BM, Hertz MI. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult lung and heart-lung transplantation report--2006. J Heart Lung Transplant. 2006;25:880–892. [PubMed]
3. Costello JM, Wax DF, Binns HJ, Backer CL, Mavroudis C, Pahl E. A comparison of intravascular ultrasound with coronary angiography for evaluation of transplant coronary disease in pediatric heart transplant recipients. J Heart Lung Transplant. 2003;22:44–49. [PubMed]
4. Vassalli G, Gallino A, Weis M, von Scheidt W, Kappenberger L, von Segesser LK, Gov JJ. Alloimmunity and nonimmunologic risk factors in cardiac allograft vasculopathy. Eur Heart J. 2003;24:1180–1188. [PubMed]
5. Morgun A, Shulzhenko N, Unterkircher CS, Diniz RV, Pereira AB, Silva MS, Nishida SK, Almeida DR, Carvalho AC, Franco M, Souza MM, Gerbase-DeLima M. Pre- and post-transplant anti-myosin and anti-heat shock protein antibodies and cardiac transplant outcome. J Heart Lung Transplant. 2004;23:204–209. [PubMed]
6. Rolls HK, Kishimoto K, Dong VM, Illigens BM, Sho M, Sayegh MH, Benichou G, Fedoseyeva EV. T-cell response to cardiac myosin persists in the absence of an alloimmune response in recipients with chronic cardiac allograft rejection. Transplantation. 2002;74:1053–1057. [PubMed]
7. Russell PS, Chase CM, Winn HJ, Colvin RB. Coronary atherosclerosis in transplanted mouse hearts. I. Time course and immunogenetic and immunopathological considerations. Am J Pathol. 1994;144:260–274. [PubMed]
8. Nicod LP. Mechanisms of airway obliteration after lung transplantation. Proc Am Thorac Soc. 2006;3:444–449. [PubMed]
9. Waaga AM, Gasser M, Laskowski I, Tilney NL. Mechanisms of chronic rejection. Curr Opin Immunol. 2000;12:517–521. [PubMed]
10. Lee RS, Yamada K, Houser SL, Womer KL, Maloney ME, Rose HS, Sayegh MH, Madsen JC. Indirect recognition of allopeptides promotes the development of cardiac allograft vasculopathy. Proc Natl Acad Sci USA. 2001;98:3276–3281. [PubMed]
11. Ciubotariu R, Liu Z, Colovai AI, Ho E, Itescu S, Ravalli S, Hardy MA, Cortesini R, Rose EA, Suciu-Foca N. Persistent allopeptide reactivity and epitope spreading in chronic rejection of organ allografts. J Clin Invest. 1998;101:398–405. [PMC free article] [PubMed]
12. Liu Z, Colovai AI, Tugulea S, Reed EF, Fisher PE, Mancini D, Rose EA, Cortesini R, Michler RE, Suciu-Foca N. Indirect recognition of donor HLA-DR peptides in organ allograft rejection. J Clin Invest. 1996;98:1150–1157. [PMC free article] [PubMed]
13. Vella JP, Spadafora-Ferreira M, Murphy B, Alexander SL, Harmon W, Carpenter CB, Sayegh MH. Indirect allorecognition of major histocompatibility complex allopeptides in human renal transplant recipients with chronic graft dysfunction. Transplantation. 1997;64:795–800. [PubMed]
14. Lee RS, Yamada K, Houser SL, Womer KL, Maloney ME, Rose HS, Sayegh MH, Madsen JC. Indirect allorecognition promotes the development of cardiac allograft vasculopathy. Transplant Proc. 2001;33:308–310. [PubMed]
15. Takemoto S, Gjertson DW, Terasaki PI. HLA matching: a comparison of conventional and molecular approaches. Clin Transpl. 1992:413–434. [PubMed]
16. Pirsch JD, D'Alessandro AM, Sollinger HW, Hoffman RM, Roecker E, Voss BJ, Lorentzen D, Knechtle SJ, Reed A, Kalayoglu M, Belzer FO. The effect of donor age, recipient age, and HLA match on immunologic graft survival in cadaver renal transplant recipients. Transplantation. 1992;53:55–59. [PubMed]
17. Hosenpud JD, Edwards EB, Lin HM, Daily OP. Influence of HLA matching on thoracic transplant outcomes. An analysis from the UNOS/ISHLT Thoracic Registry. Circulation. 1996;94:170–174. [PubMed]
18. Opelz G, Wujciak T, Dohler B, Scherer S, Mytilineos J. HLA compatibility and organ transplant survival. Collaborative Transplant Study. Rev Immunogenet. 1999;1:334–342. [PubMed]
19. Kaczmarek I, Deutsch MA, Rohrer ME, Beiras-Fernandez A, Groetzner J, Daebritz S, Schmoeckel M, Spannagl M, Meiser B, Reichart B. HLA-DR matching improves survival after heart transplantation: is it time to change allocation policies? J Heart Lung Transplant. 2006;25:1057–1062. [PubMed]
20. Husain AN, Siddiqui MT, Holmes EW, Chandrasekhar AJ, McCabe M, Radvany R, Garrity ER. Analysis of risk factors for the development of bronchiolitis obliterans syndrome. Am J Respir Crit Care Med. 1999;159:829–833. [PubMed]
21. Quantz MA, Bennett LE, Meyer DM, Novick RJ. Does human leukocyte antigen matching influence the outcome of lung transplantation? An analysis of 3,549 lung transplantations. J Heart Lung Transplant. 2000;19:473–479. [PubMed]
22. El-Gamel A, Sim E, Hasleton P, Hutchinson J, Yonan N, Egan J, Campbell C, Rahman A, Sheldon S, Deiraniya A, Hutchinson IV. Transforming growth factor beta (TGF-beta) and obliterative bronchiolitis following pulmonary transplantation. J Heart Lung Transplant. 1999;18:828–837. [PubMed]
23. Sundaresan S, Monanakumar T, Smith MA, Trulock EP, Lynch J, Phelan D, Cooper JD, Patterson GA. HLA-A locus mismatches and development of antibodies to HLA after lung transplantation correlate with the development of bronchiolitis obliterans syndrome. Transplantation. 1998;65:648–653. [PubMed]
24. Heng D, Sharples LD, McNeil K, Stewart S, Wreghitt T, Wallwork J. Bronchiolitis obliterans syndrome: incidence, natural history, prognosis, and risk factors. J Heart Lung Transplant. 1998;17:1255–1263. [PubMed]
25. Hirt SW, You XM, Moller F, Boeke K, Starke M, Spranger U, Wottge HU. Development of obliterative bronchiolitis after allogeneic rat lung transplantation: implication of acute rejection and the time point of treatment. J Heart Lung Transplant. 1999;18:542–548. [PubMed]
26. Girgis RE, Tu I, Berry GJ, Reichenspurner H, Valentine VG, Conte JV, Ting A, Johnstone I, Miller J, Robbins RC, Reitz BA, Theodore J. Risk factors for the development of obliterative bronchiolitis after lung transplantation. J Heart Lung Transplant. 1996;15:1200–1208. [PubMed]
27. Corris PA. Lung transplantation. Bronchiolitis obliterans syndrome. Chest Surg Clin N Am. 2003;13:543–557. [PubMed]
28. Kroshus TJ, Kshettry VR, Savik K, John R, Hertz MI, Bolman RM., III Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation. J Thorac Cardiovasc Surg. 1997;114:195–202. [PubMed]
29. Khalifah AP, Hachem RR, Chakinala MM, Schechtman KB, Patterson GA, Schuster DP, Mohanakumar T, Trulock EP, Walter MJ. Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am J Respir Crit Care Med. 2004;170:181–187. [PubMed]
30. Hachem RR, Khalifah AP, Chakinala MM, Yusen RD, Aloush AA, Mohanakumar T, Patterson GA, Trulock EP, Walter MJ. The significance of a single episode of minimal acute rejection after lung transplantation. Transplantation. 2005;80:1406–1413. [PubMed]
31. Kobashigawa JA, Miller L, Yeung A, Hauptman P, Ventura H, Wilensky R, Valantine H, Wiedermann J. Does acute rejection correlate with the development of transplant coronary artery disease? A multicenter study using intravascular ultrasound. Sandoz/CVIS Investigators. J Heart Lung Transplant. 1995;14:S221–S226. [PubMed]
32. Vassalli G, Gallino A, Weis M, von Scheidt W, Kappenberger L, von Segesser LK, Goy JJ. Alloimmunity and nonimmunologic risk factors in cardiac allograft vasculopathy. Eur Heart J. 2003;24:1180–1188. [PubMed]
33. Jimenez J, Kapadia SR, Yamani MH, Platt L, Hobbs RE, Rincon G, Botts-Silverman C, Starling RC, Young JB, Nissen SE, Tuzcu M, Ratliff NB. Cellular rejection and rate of progression of transplant vasculopathy: a 3-year serial intravascular ultrasound study. J Heart Lung Transplant. 2001;20:393–398. [PubMed]
34. Yamani MH, Yousufuddin M, Starling RC, Tuzcu M, Ratliff NB, Cook DJ, Abdo A, Crowe T, Hobbs R, Rincon G, Bott-Silverman C, McCarthy PM, Young JB. Does acute cellular rejection correlate with cardiac allograft vasculopathy? J Heart Lung Transplant. 2004;23:272–276. [PubMed]
35. Brunner-La Rocca HP, Schneider J, Kunzli A, Turina M, Kiowski W. Cardiac allograft rejection late after transplantation is a risk factor for graft coronary artery disease. Transplantation. 1998;65:538–543. [PubMed]
36. Dandel M, Hummel M, Wellnhofer E, Kapell S, Lehmkuhl HB, Hetzer R. Association between acute rejection and cardiac allograft vasculopathy. J Heart Lung Transplant. 2003;22:1064–1065. [PubMed]
37. Takemoto SK, Zeevi A, Feng S, Colvin RB, Jordan S, Kobashigawa J, Kupiec-Weglinski J, Matas A, Montgomery RA, Nickerson P, Platt JL, Rabb H, Thistlethwaite R, Tyan D, Delmonico FL. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant. 2004;4:1033–1041. [PubMed]
38. Michaels PJ, Espejo ML, Kobashigawa J, Alejos JC, Burch C, Takemoto S, Reed EF, Fishbein MC. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant. 2003;22:58–69. [PubMed]
39. Palmer SM, Davis RD, Hadjiliadis D, Hertz MI, Howell DN, Ward FE, Savik K, Reinsmoen NL. Development of an antibody specific to major histocompatibility antigens detectable by flow cytometry after lung transplant is associated with bronchiolitis obliterans syndrome. Transplantation. 2002;74:799–804. [PubMed]
40. Smith MA, Sundaresan S, Mohanakumar T, Trulock EP, Lynch JP, Phelan DL, Cooper JD, Patterson GA. Effect of development of antibodies to HLA and cytomegalovirus mismatch on lung transplantation survival and development of bronchiolitis obliterans syndrome. J Thorac Cardiovasc Surg. 1998;116:812–820. [PubMed]
41. Laflamme MA, Myerson D, Saffitz JE, Murry CE. Evidence for cardiomyocyte repopulation by extracardiac progenitors in transplanted human hearts. Circ Res. 2002;90:634–640. [PubMed]
42. Hillebrands JL, Klatter FA, van den Hurk BM, Popa ER, Nieuwenhuis P, Rozing J. Origin of neointimal endothelium and alpha-actin-positive smooth muscle cells in transplant arteriosclerosis. J Clin Invest. 2001;107:1411–1422. [PMC free article] [PubMed]
43. Han CI, Campbell GR, Campbell JH. Circulating bone marrow cells can contribute to neointimal formation. J Vasc Res. 2001;38:113–119. [PubMed]
44. Sata M, Saiura A, Kunisato A, Tojo A, Okada S, Tokuhisa T, Hirai H, Makuuchi M, Hirata Y, Nagai R. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med. 2002;8:403–409. [PubMed]
45. Russell PS, Chase CM, Sykes M, Ito H, Shaffer J, Colvin RB. Tolerance, mixed chimerism, and chronic transplant arteriopathy. J Immunol. 2001;167:5731–5740. [PubMed]
46. Maier S, Tertilt C, Chambron N, Gerauer K, Huser N, Heidecke CD, Pfeffer K. Inhibition of natural killer cells results in acceptance of cardiac allografts in CD28-/- mice. Nat Med. 2001;7:557–562. [PubMed]
47. Hosenpud JD, Bennett LE, Keck BM, Boucek MM, Novick RJ. The Registry of the International Society for Heart and Lung Transplantation: eighteenth Official Report-2001. J Heart Lung Transplant. 2001;20:805–815. [PubMed]
48. Horwitz MS, La Cava A, Fine C, Rodriguez E, Ilic A, Sarvetnick N. Pancreatic expression of interferon-gamma protects mice from lethal coxsackievirus B3 infection and subsequent myocarditis. Nat Med. 2000;6:693–697. [PubMed]
49. Trulock EP, Edwards LB, Taylor DO, Boucek MM, Keck BM, Hertz MI. The Registry of the International Society for Heart and Lung Transplantation: twenty-first official adult heart transplant report-2004. J Heart Lung Transplant. 2004;23:804–815. [PubMed]
50. Taylor DO, Edwards LB, Boucek MM, Trulock EP, Deng MC, Keck BM, Hertz MI. Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult heart transplant report--2005. J Heart Lung Transplant. 2005;24:945–955. [PubMed]
51. Land W, Schneeberger H, Schleibner S, Illner WD, Abendroth D, Rutili G, Arfors KE, Messmer K. The beneficial effect of human recombinant superoxide dismutase on acute and chronic rejection events in recipients of cadaveric renal transplants. Transplantation. 1994;57:211–217. [PubMed]
52. Takada M, Chandraker A, Nadeau KC, Sayegh MH, Tilney NL. The role of the B7 costimulatory pathway in experimental cold ischemia/reperfusion injury. J Clin Invest. 1997;100:1199–1203. [PMC free article] [PubMed]
53. Izutani H, Miyagawa S, Shirakura R, Matsumiya G, Nakata S, Shimazaki Y, Matsuda H. Evidence that graft coronary arteriosclerosis begins in early phase after transplantation and progresses without chronic immunoreaction. Histopathological analysis using a retransplantation model. Transplantation. 1995;60:1073–1079. [PubMed]
54. Fedoseyeva EV, Zhang F, Orr PL, Levin D, Buncke HJ, Benichou G. De novo autoimmunity to cardiac myosin after heart transplantation and its contribution to the rejection process. J Immunol. 1999;162:6836–6842. [PubMed]
55. Jurcevic S, Ainsworth ME, Pomerance A, Smith JD, Robinson DR, Dunn MJ, Yacoub MH, Rose ML. Antivimentin antibodies are an independent predictor of transplant- associated coronary artery disease after cardiac transplantation. Transplantation. 2001;71:886–892. [PubMed]
56. Haque MA, Mizobuchi T, Yasufuku K, Fujisawa T, Brutkiewicz RR, Zheng Y, Woods K, Smith GN, Cummings OW, Heidler KM, Blum JS, Wilkes DS. Evidence for immune responses to a self-antigen in lung transplantation: role of type V collagen-specific T cells in the pathogenesis of lung allograft rejection. J Immunol. 2002;169:1542–1549. [PubMed]
57. Yoshida S, Haque A, Mizobuchi T, Iwata T, Chiyo M, Webb TJ, Baldridge LA, Heidler KM, Cummings OW, Fujisawa T, Blum JS, Brand DD, Wilkes DS. Anti-type V collagen lymphocytes that express IL-17 and IL-23 induce rejection pathology in fresh and well-healed lung transplants. Am J Transplant. 2006;6:724–735. [PubMed]
58. Yasufuku K, Heidler KM, Woods KA, Smith GN, Jr, Cummings OW, Fujisawa T, Wilkes DS. Prevention of bronchiolitis obliterans in rat lung allografts by type V collagen-induced oral tolerance. Transplantation. 2002;73:500–505. [PubMed]
59. Billings JL, Hertz MI, Savik K, Wendt CH. Respiratory viruses and chronic rejection in lung transplant recipients. J Heart Lung Transplant. 2002;21:559–566. [PubMed]
60. Garbino J, Gerbase MW, Wunderli W, Kolarova L, Nicod LP, Rochat T, Kaiser L. Respiratory viruses and severe lower respiratory tract complications in hospitalized patients. Chest. 2004;125:1033–1039. [PubMed]
61. Fujinami RS, Nelson JA, Walker L, Oldstone MB. Sequence homology and immunologic cross-reactivity of human cytomegalovirus with HLA-DR beta chain: a means for graft rejection and immunosuppression. Journal of Virology. 1988;62:100–105. [PMC free article] [PubMed]
62. Schulman LL, Weinberg AD, McGregor CC, Suciu-Foca NM, Itescu S. Influence of donor and recipient HLA locus mismatching on development of obliterative bronchiolitis after lung transplantation. Am J Respir Crit Care Med. 2001;163:437–442. [PubMed]
63. Ison MG, Fishman JA. Cytomegalovirus pneumonia in transplant recipients. Clin Chest Med. 2005;26:691–705. [PubMed]
64. Subramanian AK, Quinn TC, Kickler TS, Kasper EK, Tucker PC. Correlation of chlamydia pneumoniae infection and severity of accelerated graft arteriosclerosis after cardiac transplantation. Transplantation. 2002;73:761–764. [PubMed]
65. Grattan MT, Moreno CC, Starnes VA, Oyer PE, Stinson EB, Shumway NE. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA. 1989;261:3561–3566. [PubMed]
66. Valantine HA, Gao SZ, Menon SG, Renlund DG, Hunt SA, Oyer P, Stinson EB, Brown BW, Jr, Merigan TC, Schroeder JS. Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. Circulation. 1999;100:61–66. [PubMed]
67. Berkowitz N, Schulman LL, McGregor C, Markowitz D. Gastroparesis after lung transplantation. Potential role in postoperative respiratory complications. Chest. 1995;108:1602–1607. [PubMed]
68. Davis RD, Jr, Lau CL, Eubanks S, Messier RH, Hadjiliadis D, Steele MP, Palmer SM. Improved lung allograft function after fundoplication in patients with gastroesophageal reflux disease undergoing lung transplantation. J Thorac Cardiovasc Surg. 2003;125:533–542. [PubMed]
69. Hartwig MG, Appel JZ, Li B, Hsieh CC, Yoon YH, Lin SS, Irish W, Parker W, Davis RD. Chronic aspiration of gastric fluid accelerates pulmonary allograft dysfunction in a rat model of lung transplantation. J Thorac Cardiovasc Surg. 2006;131:209–217. [PubMed]
70. Halloran PH, Melk A, Barth C. Rethinking chronic allograft nephropathy: the concept of accelerated senescence. J Am Soc Nephrol. 1999;10:167–181. [PubMed]
71. Wilhelm MJ, Pratschke J, Beato F, Taal M, Laskowski LA, Paz DM, Schmid C, Hancock WW, Scheld HH, Tilney NL. Activation of proinflammatory mediators in heart transplants from brain-dead donors: evidence from a model of chronic rat cardiac allograft rejection. Transplant Proc. 2002;34:2359–2360. [PubMed]
72. Takada M, Nadeau KC, Hancock WW, Mackenzie HS, Shaw GD, Waaga AM, Chandraker A, Sayegh MH, Tilney NL. Effects of explosive brain death on cytokine activation of peripheral organs in the rat. Transplantation. 1998;65:1533–1542. [PubMed]
73. Zweers N, Petersen AH, van der Hoeven JA, De Haan A, Ploeg RJ, de Leij LF, Prop J. Donor brain death aggravates chronic rejection after lung transplantation in rats. Transplantation. 2004;78:1251–1258. [PubMed]
74. Anyanwu AC, Banner NR, Mitchell AG, Khaghani A, Yacoub MH. Low incidence and severity of transplant-associated coronary artery disease in heart transplants from live donors. J Heart Lung Transplant. 2003;22:281–286. [PubMed]
75. Segel LD, vonHaag DW, Zhang J, Follette DM. Selective overexpression of inflammatory molecules in hearts from brain-dead rats. J Heart Lung Transplant. 2002;21:804–811. [PubMed]
76. Woo MS, MacLaughlin EF, Horn MV, Szmuszkovicz JR, Barr ML, Starnes VA. Bronchiolitis obliterans is not the primary cause of death in pediatric living donor lobar lung transplant recipients. J Heart Lung Transplant. 2001;20:491–496. [PubMed]
77. Mehra MR, Uber PA, Ventura HO, Scott RL, Park MH. The impact of mode of donor brain death on cardiac allograft vasculopathy: an intravascular ultrasound study. J Am Coll Cardiol. 2004;43:806–810. [PubMed]